A.P. Pharma, Inc. (OTCBB:APPA.OB), a specialty pharmaceutical company, announced that Barry Quart, Pharm D., the Company's Chief Executive Officer, will be presenting at the Eighth Annual JMP Securities Healthcare Conference on Tuesday, July 9, 2013 in New York City.
The following are specific details regarding A.P. Pharma’s presentation at the conference:
JMP Securities Healthcare Conference
|Date:||July 9 th, 2013|
|Time:||4.30 – 4.55 pm ET|
|Location:||Library Room, St. Regis Hotel, New York, NY.|
A live webcast of the presentation can be accessed through the “Investors” section of the Company's website at www.appharma.com. Following the live presentation, a replay of the webcast will be available on the website.
The JMP Securities Annual Healthcare Conference is an institutional investor forum featuring more than 125 publicly traded and privately held companies in the areas of biotechnology and medical devices. More information can be found at www.jmpg.com/jmpsecurities/about/conferences/.About A.P. Pharma A.P. Pharma is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks. The Company’s lead product candidate, APF530, is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. For further information, please visit the Company's web site at www.appharma.com. Forward-looking Statements This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, including uncertainties associated with the potential approval of APF530 and the potential timing for such approval, if approved at all, the projected timing for the commercial launch of APF530, if approved, as well as risks relating to capital resources and liquidity, satisfactory completion of clinical studies, progress in research and development programs, successful launch and acceptance of new products and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. We caution investors that forward-looking statements reflect our analysis only on their stated date. We do not intend to update them except as required by law.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts